Stockreport

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 ...

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three yearsDESTINY-Breast05 presented in ESMO Presidenti [Read more]